Dr. Reddy's Laboratories has signed an agreement with Shenzhen Pregene Biopharma to acquire an exclusive license in India for PRG1801, Pregene's single domain antibody-based anti-BCMA chimeric antigen receptor T (CAR-T) cell therapy injection.
14 May 2021
20 Apr 2021
The second indication of Sarclisa (isatuximab) for the treatment of adult patients with relapsed multiple myeloma, was approved by the European Commission (EC).
14 Apr 2021
Gilead Sciences has announced the accelerated approval of Trodelvy (or sacituzumab govitecan-hziy) by the US Food and Drug Administration (FDA) in the treatment of locally advanced or metastatic urothelial cancer (UC) in adult patients.
12 Apr 2021
Global biopharmaceutical company Sanofi has acquired privately owned, pre-clinical stage biotech company Tidal Therapeutics, which brings with it an mRNA-based approach for in vivo (inside the body) reprogramming of immune cells.
06 Apr 2021
Biotechnology company Anixa Biosciences, partnered by IT and pharma solutions company OntoChem, has announced that it will enter the next stage of development of its potential anti-viral therapy for Covid-19.
30 Mar 2021
Merck has announced that the US Food and Drug Administration (FDA) has sent a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) for the approval of KEYTRUDA.
18 Mar 2021
The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive gastric cancer.
17 Mar 2021
The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan.
11 Mar 2021
Enveric Biosciences has announced that it has signed an exclusive, perpetual licensing agreement with Diverse Biotech to develop new molecules for the treatment of cancer and other debilitating diseases.
10 Mar 2021
Japan-based Takeda Pharmaceutical Company Limited has entered into an agreement to acquire private biopharmaceutical company Maverick Therapeutics, Inc. in a bid to expand its novel immuno-oncology portfolio.